UNSPSC 51182710: Metformin/linagliptin

Metformin/linagliptin is a combination of an agent of the biguanide class and a DPP-4 inhibitor used to treat high blood sugar levels caused by type 2 diabetes.

UNSPSC 51182710 Metformin/linagliptin, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The source contains a single pharmaceutical-services opportunity directly relevant to the code's nominal scope—Dane County's RFP for comprehensive pharmaceutical services at Badger Prairie Health Care Center, a long-term care facility, with proposals due October 22, 2026—alongside multiple unrelated opportunities including emergency medicine software procurement (Collier County), pharmacy benefits administration (District of Columbia), procurement conference registration (Clay County), aquatic facility operations (Palm Bay), and opioid-settlement grant administration (Bernalillo County). Only the Dane County solicitation represents actual procurement of pharmaceutical products and services.

Dane County's RFP reflects typical long-term care pharmacy contracting: the county seeks a vendor to provide daily medication deliveries with one-hour stat-order fulfillment, medication dispensing and management with barcode scanning, secure web portal prescription communication, and quality-assurance participation across five one-year terms from January 1, 2027 through December 31, 2031. The County currently budgets $125,000 annually for pharmaceutical services and applies a local-vendor preference (five bonus evaluation points for Dane County vendors, two points for adjacent-county vendors). Evaluation emphasizes organizational qualifications, service delivery approach, staffing and support, cost, and technology integration, with the vendor required to provide all equipment at no cost to the facility and accept Medicaid and Medicare Part D payments as payment in full. The source provides no evidence of concentrated activity or repeat buyers under this commodity code; the code's recent opportunities signal minimal state and local procurement volume or systematic tagging misalignment rather than a market signal worth pursuing at this time.